Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

PARP Inhibitor Sensitizes BRCA-mutant Pancreatic Cancer to Oxaliplatin by Suppressing the CDK1/BRCA1 Axis

CHORONG KIM, DANBEE KIM, DA SOL LEE, SEONMIN LEE, CHANGHOON YOO and KYU-PYO KIM
Anticancer Research December 2023, 43 (12) 5523-5534; DOI: https://doi.org/10.21873/anticanres.16754
CHORONG KIM
1Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DANBEE KIM
2Division of Research Program, Scripps Korea Antibody Institute, Gangwon-do, Republic of Korea;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DA SOL LEE
1Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SEONMIN LEE
3Digestive Diseases Research Center, University of Ulsan College of Medicine, Seoul, Republic of Korea;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHANGHOON YOO
4Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KYU-PYO KIM
4Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: kkp1122@amc.seoul.kr
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 43 no. 12 5523-5534
DOI 
https://doi.org/10.21873/anticanres.16754
PubMed 
38030179

Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received July 18, 2023
  • Revision received October 5, 2023
  • Accepted October 6, 2023
  • Published online November 29, 2023.

Copyright & Usage 
Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Author Information

  1. CHORONG KIM1,*,
  2. DANBEE KIM2,*,
  3. DA SOL LEE1,
  4. SEONMIN LEE3,
  5. CHANGHOON YOO4 and
  6. KYU-PYO KIM4⇑
  1. 1Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea;
  2. 2Division of Research Program, Scripps Korea Antibody Institute, Gangwon-do, Republic of Korea;
  3. 3Digestive Diseases Research Center, University of Ulsan College of Medicine, Seoul, Republic of Korea;
  4. 4Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
  1. Correspondence to: Kyu-Pyo Kim, Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Republic of Korea. Tel: +82 230105913, Fax: +82 220454046, e-mail: kkp1122{at}amc.seoul.kr
  1. ↵* These Authors contributed equally to this work.

View Full Text

Statistics from Altmetric.com

Cited By...

  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

PreviousNext
Back to top

In this issue

Anticancer Research: 43 (12)
Anticancer Research
Vol. 43, Issue 12
December 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
PARP Inhibitor Sensitizes BRCA-mutant Pancreatic Cancer to Oxaliplatin by Suppressing the CDK1/BRCA1 Axis
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
9 + 7 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
PARP Inhibitor Sensitizes BRCA-mutant Pancreatic Cancer to Oxaliplatin by Suppressing the CDK1/BRCA1 Axis
CHORONG KIM, DANBEE KIM, DA SOL LEE, SEONMIN LEE, CHANGHOON YOO, KYU-PYO KIM
Anticancer Research Dec 2023, 43 (12) 5523-5534; DOI: 10.21873/anticanres.16754

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
PARP Inhibitor Sensitizes BRCA-mutant Pancreatic Cancer to Oxaliplatin by Suppressing the CDK1/BRCA1 Axis
CHORONG KIM, DANBEE KIM, DA SOL LEE, SEONMIN LEE, CHANGHOON YOO, KYU-PYO KIM
Anticancer Research Dec 2023, 43 (12) 5523-5534; DOI: 10.21873/anticanres.16754
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Predictive Factors for Multiple Metastases of Clear-cell Renal Cell Carcinoma
  • Acyclic Retinoid Overcomes Vemurafenib Resistance in Melanoma Cells via Dual Inhibition of MAPK and PI3K/AKT/mTOR Pathways
  • Tumor Immunology Visualized in Realtime in In-vivo-like 3-D Gelfoam® Histoculture by Color-coded Imaging
Show more Experimental Studies

Similar Articles

Keywords

  • pancreatic cancer
  • BRCA2
  • olaparib
  • oxaliplatin
  • synthetic lethality
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire